ArticleFrontiers in pharmacology2026
Protection against cisplatin-induced acute kidney injury by hellgrammite extract: insights from comprehensive metabolomics.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin (CP), a highly potent antineoplastic agent, is severely limited in clinical use by dose-limiting toxicities, particularly acute kidney injury (AKI Methods: We first evaluated the nutritional profile of Hel using high-performance liquid chromatography (HPLC) for amino acid composition analysis. Subsequently, a mouse model of CP-induced AKI was treated with different doses of Hel by gavage, then traditional pharmacology, and metabolomics were used to elucidate the effects and mechanism of Hel on CP-induced AKI mice. Results: Hel effectively ameliorated CP-induced alterations in biochemical indicators and alleviated kidney pathological changes. Hel administration rectified the kidney metabolic disturbances induced by CP, involving alterations in 38 differential metabolites associated with glycerophospholipid metabolism, purine metabolism, nicotinate and nicotinamide metabolism, and thiamine metabolism. Discussion: Hel confers renoprotection by reversing metabolic disorders in CP-induced AKI, revealing actionable targets for AKI intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.